Shares of China Biologic Products Inc. (NASDAQ:CBPO) fell 1.5% on Monday . The company traded as low as $123.57 and last traded at $123.76, with a volume of 92,368 shares traded. The stock had previously closed at $125.64.

A number of research firms recently weighed in on CBPO. Zacks Investment Research upgraded shares of China Biologic Products from a “hold” rating to a “buy” rating and set a $141.00 target price on the stock in a research note on Wednesday, August 10th. Jefferies Group upped their target price on shares of China Biologic Products from $136.00 to $155.00 and gave the stock a “buy” rating in a research note on Friday, August 5th. Finally, Credit Suisse Group AG upgraded shares of China Biologic Products from a “neutral” rating to an “outperform” rating in a research note on Tuesday, July 5th.

The company has a market cap of $3.28 billion and a P/E ratio of 35.13. The company’s 50-day moving average is $116.71 and its 200 day moving average is $115.49.

China Biologic Products (NASDAQ:CBPO) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.16 by $0.10. During the same period in the previous year, the business posted $1.06 earnings per share. The business earned $91.40 million during the quarter, compared to analyst estimates of $87.60 million. The firm’s quarterly revenue was up 15.6% on a year-over-year basis. Equities research analysts anticipate that China Biologic Products Inc. will post $4.18 EPS for the current fiscal year.

In other news, CFO Ming Yang sold 13,908 shares of China Biologic Products stock in a transaction dated Friday, May 20th. The stock was sold at an average price of $113.64, for a total value of $1,580,505.12. Following the transaction, the chief financial officer now directly owns 52,282 shares of the company’s stock, valued at approximately $5,941,326.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Wp X. Biologics Llc sold 2,775,000 shares of China Biologic Products stock in a transaction dated Wednesday, June 8th. The shares were sold at an average price of $111.00, for a total value of $308,025,000.00. The disclosure for this sale can be found here.

A hedge fund recently bought a new stake in China Biologic Products stock. Employees Retirement System of Texas purchased a new stake in China Biologic Products Inc. (NASDAQ:CBPO) during the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 20,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,846,000. Employees Retirement System of Texas owned about 0.08% of China Biologic Products at the end of the most recent reporting period.

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.